LeMaitre Vascular (LMAT)
(Delayed Data from NSDQ)
$66.24 USD
+0.78 (1.19%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $66.33 +0.09 (0.14%) 4:50 PM ET
1-Strong Buy of 5 1
D Value C Growth D Momentum D VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
LMAT 66.24 +0.78(1.19%)
Will LMAT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for LMAT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LMAT
AtriCure's (ATRC) cryoSPHERE+ Probe to Aid in Pain Management
Here's Why You Should Retain Medtronic (MDT) Stock for Now
LMAT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why You Should Hold BD (BDX) Stock in Your Portfolio
Baxter's (BAX) New Injectables Aid Its Pharmaceutical Portfolio
Here's Why You Should Add DaVita (DVA) to Your Portfolio
Other News for LMAT
Buy Rating Affirmed: LeMaitre Vascular’s Growth and Profitability Outlook
LeMaitre just upgraded at Stifel, here's why
Doubling Down On Telus In Smith Maneuver - March 2024 Dividend Income Report
LeMaitre Will Announce First Quarter 2024 Earnings Results May 2, 2024
Staar Surgical Co's Meteoric Rise: Unpacking the 52% Surge in Just 3 Months